These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29870627)

  • 21. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
    Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
    J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
    Kermer P; Eschenfelder CC; Diener HC; Grond M; Abdalla Y; Abraham A; Althaus K; Becks G; Berrouschot J; Berthel J; Bode FJ; Burghaus L; Cangür H; Daffertshofer M; Edelbusch S; Eggers J; Gerlach R; Gröschel K; Große-Dresselhaus F; Günther A; Haase CG; Haensch CA; Harloff A; Heckmann JG; Held V; Hieber M; Kauert A; Kern R; Kerz T; Köhrmann M; Kraft P; Kühnlein P; Latta J; Leinisch E; Lenz A; Leithner C; Neumann-Haefelin T; Mäurer M; Müllges W; Nolte CH; Obermann M; Partowi S; Patzschke P; Poli S; Pulkowski U; Purrucker J; Rehfeldt T; Ringleb PA; Röther J; Rossi R; El-Sabassy H; Sauer O; Schackert G; Schäfer N; Schellinger PD; Schneider A; Schuppner R; Schwab S; Schwarte O; Seitz RJ; Senger S; Shah YP; Sindern E; Sparenberg P; Steiner T; Szabo K; Urbanek C; Sarnowksi BV; Weissenborn K; Wienecke P; Witt K; Wruck R; Wunderlich S
    Int J Stroke; 2020 Aug; 15(6):609-618. PubMed ID: 31955706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab.
    Berrouschot J; Stoll A; Hogh T; Eschenfelder CC
    Stroke; 2016 Jul; 47(7):1936-8. PubMed ID: 27301937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idarucizumab: First Global Approval.
    Burness CB
    Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
    van der Wall SJ; van Rein N; van den Bemt B; Kruip MJHA; Meijer K; Te Boome LCJ; Simmers TA; Alings AMW; Tieleman R; Klok FA; Huisman MV; Westerweel PE
    Europace; 2019 Mar; 21(3):414-420. PubMed ID: 30339226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant.
    Finks SW; Rogers KC
    Am J Med; 2017 May; 130(5):e195-e197. PubMed ID: 28011314
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
    Meyer D; Chu F; Derry K; Hailey L
    J Clin Neurosci; 2019 Jan; 59():355-357. PubMed ID: 30309801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
    Bissig D; Manjunath R; Traylor BR; Richman DP; Ng KL
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safe Burr Hole Surgery for Chronic Subdural Hematoma Using Dabigatran with Idarucizumab.
    Arai N; Mine Y; Kagami H; Maruyama M; Daikoh A; Inaba M
    World Neurosurg; 2018 Jan; 109():432-435. PubMed ID: 29054780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.
    Na SY; Mracsko E; van Ryn J; Veltkamp R
    Ann Neurol; 2015 Jul; 78(1):137-41. PubMed ID: 25899749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of hemorrhage in patients treated with direct oral anticoagulants].
    Grottke O; Lier H; Hofer S
    Anaesthesist; 2017 Sep; 66(9):679-689. PubMed ID: 28455651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
    Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.
    Ohya Y; Makihara N; Wakisaka K; Morita T; Ago T; Kitazono T; Takaba H
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):e128-e131. PubMed ID: 29555397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study.
    Jala S; O'Brien E
    J Neurosci Nurs; 2019 Feb; 51(1):21-25. PubMed ID: 30489421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
    Rosenberg L; Gerstrøm G; Nybo M
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.